Soluble Transferrin Receptor Investigated in Iron Deficiency Anemia
|
By LabMedica International staff writers Posted on 25 May 2020 |

Image: The UniCel DxI 800 Access Immunoassay System (Photo courtesy of Beckman Coulter).
Anemia is a global public health problem and approximately 30% of the world's population suffered from anemia, with children and pregnant women being the most affected. Microcytic hypochromic anemia is a common type of anemia, and iron deficiency anemia (IDA) is the most common manifestation of this anemia.
The current gold standard for an IDA diagnosis is iron staining of a bone marrow smear. Transferrin receptor (TfR) is a transmembrane glycoprotein. Iron is transported by binding to specific TfR‐transferrin complex and thereby released into cells. Through proteolysis, TfR produces soluble transferrin receptor (sTfR) in the serum, whose concentration is proportional to the TfR concentration.
Laboratory medical scientists at the Peking Union Medical College Hospital (Beijing, China) enrolled 436 subjects from March 2014 to August 2015. Among these, 118 were patients with IDA, 161 were patients with anemia of chronic disease (ACD), 60 were patients with chronic diseases with iron deficiency anemia (CIDA), and 97 were apparently healthy subjects (HS).
The scientists used the DXI 800 automatic immunoassay analyzer (Beckman Coulter, Brea, CA, USA), the Cobas c702 automatic biochemistry analyzer (Roche Diagnostics, Risch-Rotkreuz, Switzerland), and the Siemens BNII special protein analyzer (Siemens Healthineers, Erlangen, Germany) with their corresponding sTfR reagents and calibrators. The sTfR concentrations in two groups of patient specimens with high‐level and low‐level sTfR concentrations and in quality control materials were measured four times a day for five consecutive days to evaluate the precision of the three methods.
The investigators reported that for the diagnosis of IDA, the cutoff points of sTfR measured by the chemiluminescent, immunoturbidimetric, and immunonephelometric assays were 2.91, 6.70, and 2.48 mg/L, respectively. The corresponding sensitivities were 85.59%, 85.59%, and 85.59%, the specificities were 91.47%, 90.31%, and 90.70%, and area under the curve was 0.943, 0.944, and 0.936, respectively. The sTfR concentrations measured by the different methods were significantly higher in the IDA and CIDA groups than in the other two groups.
The authors concluded that the different sTfR measurement methods showed similar diagnostic value in diagnosing iron deficiency and identifying whether ACD was combined with iron deficiency. However, there were large differences in the measurement results obtained with the different methods, and their cutoff points also varied. Therefore, when sTfR is used in the course of clinical diagnosis and treatment and to establish relevant diagnostic criteria and guidelines, clinicians should pay attention to the differences in the results between different measurement methods. The study was first published on April 22, 2020 in the Journal of Clinical Laboratory Analysis.
The current gold standard for an IDA diagnosis is iron staining of a bone marrow smear. Transferrin receptor (TfR) is a transmembrane glycoprotein. Iron is transported by binding to specific TfR‐transferrin complex and thereby released into cells. Through proteolysis, TfR produces soluble transferrin receptor (sTfR) in the serum, whose concentration is proportional to the TfR concentration.
Laboratory medical scientists at the Peking Union Medical College Hospital (Beijing, China) enrolled 436 subjects from March 2014 to August 2015. Among these, 118 were patients with IDA, 161 were patients with anemia of chronic disease (ACD), 60 were patients with chronic diseases with iron deficiency anemia (CIDA), and 97 were apparently healthy subjects (HS).
The scientists used the DXI 800 automatic immunoassay analyzer (Beckman Coulter, Brea, CA, USA), the Cobas c702 automatic biochemistry analyzer (Roche Diagnostics, Risch-Rotkreuz, Switzerland), and the Siemens BNII special protein analyzer (Siemens Healthineers, Erlangen, Germany) with their corresponding sTfR reagents and calibrators. The sTfR concentrations in two groups of patient specimens with high‐level and low‐level sTfR concentrations and in quality control materials were measured four times a day for five consecutive days to evaluate the precision of the three methods.
The investigators reported that for the diagnosis of IDA, the cutoff points of sTfR measured by the chemiluminescent, immunoturbidimetric, and immunonephelometric assays were 2.91, 6.70, and 2.48 mg/L, respectively. The corresponding sensitivities were 85.59%, 85.59%, and 85.59%, the specificities were 91.47%, 90.31%, and 90.70%, and area under the curve was 0.943, 0.944, and 0.936, respectively. The sTfR concentrations measured by the different methods were significantly higher in the IDA and CIDA groups than in the other two groups.
The authors concluded that the different sTfR measurement methods showed similar diagnostic value in diagnosing iron deficiency and identifying whether ACD was combined with iron deficiency. However, there were large differences in the measurement results obtained with the different methods, and their cutoff points also varied. Therefore, when sTfR is used in the course of clinical diagnosis and treatment and to establish relevant diagnostic criteria and guidelines, clinicians should pay attention to the differences in the results between different measurement methods. The study was first published on April 22, 2020 in the Journal of Clinical Laboratory Analysis.
Latest Clinical Chem. News
- New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
- Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
- Study Compares Analytical Performance of Quantitative Hepatitis B Surface Antigen Assays
- Blood Test Could Predict and Identify Early Relapses in Myeloma Patients
- Compact Raman Imaging System Detects Subtle Tumor Signals
- Noninvasive Blood-Glucose Monitoring to Replace Finger Pricks for Diabetics
- POC Breath Diagnostic System to Detect Pneumonia-Causing Pathogens
- Online Tool Detects Drug Exposure Directly from Patient Samples
- Chemical Imaging Probe Could Track and Treat Prostate Cancer
- Mismatch Between Two Common Kidney Function Tests Indicates Serious Health Problems
- VOCs Show Promise for Early Multi-Cancer Detection
- Portable Raman Spectroscopy Offers Cost-Effective Kidney Disease Diagnosis at POC
- Gold Nanoparticles to Improve Accuracy of Ovarian Cancer Diagnosis
- Simultaneous Cell Isolation Technology Improves Cancer Diagnostic Accuracy
- Simple Non-Invasive Hair-Based Test Could Speed ALS Diagnosis
- Paper Strip Saliva Test Detects Elevated Uric Acid Levels Without Blood Draws
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







